November 11, 2004
SpeculatingStocks.com Stock Pick: Geron Corporation (GERN)
Stock Price: $7.30 (long-term strong buy)
Geron is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for cancer based on its telomerase technology, and cell-based therapeutics using its human embryonic stem cell technology.
GERN did not really participate in the recent stem cell run. STEM went up over 238% before the election. The run higher was almost all based on the speculation that John Kerry would be elected. However, STEM held onto some of its gains and is still ahead of GERN in gains as of late.
Geron Corp has a number of patents that will allow the company to fight cancer in the future. We expect GERN to benefit from Proposal 71 stem cell funding in California as well.
SpeculatingStocks.com Target Price: We believe GERN will run over $14.00 within the next 3-6 months.